Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windlas BiotechNSE:WINDLAS -0.71%87 Return-on-Tangible-Asset is 7.10% as of Mar. 2026, which is 18% below its 10-year median of 8.63. GuruFocus rates NSE:WINDLAS with a GF Score™ of 87/100 and a GF Value™ of ₹942.31 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,007 Drug Manufacturers companies, Windlas Biotech ranks better than 71.7% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Windlas Biotech's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹640 Mil. Windlas Biotech's average total tangible assets for the quarter that ended in Mar. 2026 was ₹9,004 Mil. Therefore, Windlas Biotech's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 7.10%.
The historical rank and industry rank for Windlas Biotech's Return-on-Tangible-Asset or its related term are showing as below:
NSE:WINDLAS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5 Med: 8.63 Max: 21.44
Current: 8.1
During the past 8 years, Windlas Biotech's highest Return-on-Tangible-Asset was 21.44%. The lowest was 5.00%. And the median was 8.63%.
NSE:WINDLAS's Return-on-Tangible-Asset is ranked better than 71.7% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs NSE:WINDLAS: 8.10
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Windlas Biotech Return-on-Tangible-Asset Related Terms
Windlas Biotech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WINDLAS vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 7.10% mean?
Windlas Biotech (NSE:WINDLAS) has a Return-on-Tangible-Asset of 7.10% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Windlas Biotech and its competitors. This is 18% below median its historical median of 8.63. Over the past decade, Windlas Biotech's Return-on-Tangible-Asset has ranged from 5.00 to 21.44. According to the industry distribution chart, Windlas Biotech ranks #285 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 28.3%.
Is Windlas Biotech's Return-on-Tangible-Asset too high?
Windlas Biotech's current Return-on-Tangible-Asset of 7.10% is 18% below median its 10-year median of 8.63. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 21.44. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Windlas Biotech's value of 7.10% is 124.7% above this industry median. Based on the distribution chart, Windlas Biotech ranks #285 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #285 out of 1007 companies for Return-on-Tangible-Asset. This puts Windlas Biotech in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.16. Windlas Biotech's value of 7.10% is 124.7% above this benchmark. Historically, Windlas Biotech's own Return-on-Tangible-Asset has ranged from 5.00 to 21.44 over the past decade. While the company's 10-year median is 8.63 vs. the industry median of 3.16, Windlas Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current Return-on-Tangible-Asset of 7.10% is 124.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Return-on-Tangible-Asset is 7.10%, which is 18% below median its own 10-year median of 8.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹942.31, compared to a current price of ₹844.25 — trading 10.4% below its estimated fair value. The current Return-on-Tangible-Asset is 7.10%, which is 18% below median its 10-year median of 8.63 and 124.7% above the Drug Manufacturers industry median of 3.16. Windlas Biotech's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Return-on-Tangible-Asset is 7.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹844.25 is trading 10.4% below its estimated GF Value™ of ₹942.31.
GuruFocus considers Windlas Biotech to be Modestly Undervalued.
Key valuation signals for NSE:WINDLAS:
Return-on-Tangible-Asset: 7.10% (18% below median its 10-year median of 8.63)
GF Value™: ₹942.31 vs. price of ₹844.25 (10.4% below fair value)
Industry Position: 124.7% above the Drug Manufacturers median (#285 of 1007)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
87GF Score
Get the complete analysis for NSE:WINDLAS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
